bioLytical prototypes on 60-second Zika diagnostic Tests

March 22, 2016 – RICHMOND, BC. bioLytical Laboratories, a world leader in rapid infectious disease tests, has successfully developed a pre-clinical prototype assay for the detection of antibodies to the Zika virus.  The test is able to detect anti-Zika antibodies in patient samples collected shortly after the onset of symptoms, indicating detection of IgM, which is critical for identification of early stages of infection.   

The prototype is developed on the Company’s proven, accurate, and highly accepted INSTI rapid test platform, which is capable of providing results in as little as 60 seconds.  The pre-clinical test successfully detected anti-Zika antibodies from infected patient serum or plasma with minimal cross-reactivity with confirmed positive anti-Dengue or anti-Chikungunya sera.  Additional successful prototypes were created for detection of anti-Dengue and anti-Chikungunya antibodies, providing the option to develop either a multiplex test to simultaneously detect Zika, Dengue and Chikungunya virus infections, or individual stand-alone pathogen-specific tests.  With this successful proof of concept, the company is evaluating opportunities to accelerate the development of a Zika/Flavivirus test that would expand the INSTI rapid testing menu to include a response to this unmet public health need.  

“We are extremely excited about the INSTI platform’s demonstration of early qualitative detection of these flaviviral infections.  The INSTI technology can detect IgM and IgG antibodies from fingerstick or venipuncture whole blood, plasma or serum,” Rick Galli, bioLytical’s Chief Technical Officer said in a statement. “We aim to be the first company to successfully develop a point of care diagnostic test which can provide results for Zika, Dengue and Chikungunya infections in 60 seconds.”  

The Flaviviridae family has become a major concern in many areas of South America.  As of early February 2016, the Brazil Ministry of Health has estimated that 500,000 to 1,500,000 cases of Zika virus disease have occurred since the beginning of the outbreak.1  Similarly, dengue has increased 30-fold over the last 50 years, which totals to an estimated 50-100 million infections annually in over 100 endemic countries.2  Comparably, since 2013, local transmission of Chikungunya has been identified in 45 countries or territories throughout the Americas with more than 1.7 million suspected cases.3  With the emergence and co-existence of these three diseases in a single population, a diagnostic assay that can rapidly detect and differentiate between them is of upmost importance.

Source: bioLytical Laboratories